🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against superbug strains of the infection, according to scientists.

A Global Health Concern

Cases of gonorrhoea are escalating worldwide, with data suggesting more than 82 million infections annually. Particularly high rates are reported in Africa and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce treatment choices currently available.”

Public health authorities are particularly alarmed about the rise in treatment-resistant strains. The WHO has designated it as a "critical concern". A tracking program found that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Secure Approval

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in mid-December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in close succession. This treatment, which is also used to treat urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a innovative non-profit model for drug creation. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This milestone signifies a huge turning point in the therapy of highly resistant gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Clinical Trial Outcomes and Global Access

As per results detailed in a prominent scientific publication, zoliflodacin eradicated more than 90% of cases of the STI. This establishes an similar efficacy with the existing first-line therapy, which combines two antibiotics. The study involved over 900 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the authority to register and commercialise the drug in many regions with limited resources.

Doctors on the front lines have voiced optimism. The availability of a one-pill regimen such as this is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as vital to alleviate the strain of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea around the world.